🔴 ABIVAX is trading 4.16% down today after disappointing Ionis trial results

ABIVAX is trading at €95.50, down 4.16%, as broader biotech weakness intensified on September 15, 2026, following disappointing Ionis Pharmaceuticals trial results.

• The sector is also pressured by analyst downgrades and weaker sentiment toward commercial-stage biotech companies.
• Bank of America disclosed on September 14 that its stake had fallen below 5%, potentially adding selling pressure.
• No new ABIVAX-specific clinical or regulatory setback was reported.